Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes.

Stephen C L Gough et al.PubMed ↗Publisher ↗

What the trial testedas reported · 1,663 people · 2014

Not counted

−0.47percentage points−0.58 to −0.36

As reported

difference −0.47 %, 95% CI −0.58 to −0.36

the abstract, start to end

… degludec (estimated treatment difference -0.47%, 95% CI -0.58 to -0.36, …

← favours treatmentfavours comparator →

could be chance

Glycemic control

−0.47−0.58 to −0.36

GLP-1 receptor agonistsInsulinGlycemic control

1 / 3

2014

…

2015

2016

2017

2018

2019

2020

2021

2022

2023

2024

2025

2026

this paperpooled ittrialcites it